We partner to deliver innovative medicines that transform patients’ lives.
We have established an excellent track record of in-licensing and out-licensing deals with our global and regional partners.
Global Strategic Partnership with Abbvie
One of the Largest Out-license Deals in Biotech Sector
Total aggregate value under the agreement> $1.94B + $1B*
This deal reinforces I-Mab’s leading position in immuno-oncology and enables us to realize the full potential of our innovation globally.
AbbVie obtains Ex-Greater China rights to develop and commercialize lemzoparlimab; I-Mab retains Greater China rights.
* AbbVie has a right of first negotiation to in-license further development and commercialization of two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by I-Mab. The potential value of each such license is a minimum of US$500 million in upfront and milestone payments, for a combined total of no less than US$1 billion.
Commercial Partnership with Jumpcan
Among China’s Largest Partnering Deals
Total aggregate value under the agreement$315M + Royalties / Shared Profits*
This deal brings together the strengths of I-Mab’s leadership in innovation and Jumpcan’s leadership in pediatric medicine in China to accelerate the commercialization of eftansomatropin alfa.
* Jumpcan pays US$35 million upfront and US$280 miilion upon development, registration, and sales milestone achievements. Sharing profits on a 50/50 basis, I-Mab is entitled to receive tiered low double-digit royalties on net sales of product.
Partner with Us
We are currently seeking strategic partners in the following areas
- In-licensing highly differentiated oncology assets
- Co-development and co-commercialization of our innovative products for the global market